{"id":881529,"date":"2025-09-03T11:53:00","date_gmt":"2025-09-03T15:53:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/"},"modified":"2025-09-03T11:53:00","modified_gmt":"2025-09-03T15:53:00","slug":"enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/","title":{"rendered":"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference"},"content":{"rendered":"

<\/p>\n

Enveric Biosciences to Present at H.C. Wainwright 27th <\/sup>Annual Global Investment Conference<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nEnveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.<\/p>\n

\nIn the prerecorded presentation, Dr. Tucker will provide updates and discuss progress for the Company’s pipeline of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003. Enveric designed EB-003 to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. EB-003 also offers a potential dual-targeting mechanism of action, with data demonstrating partial agonism at the 5-HT\u2082A <\/sub>receptor and agonism at the 5-HT\u2081B <\/sub>receptor.<\/p>\n

\nDetails of the presentation are as follows:<\/p>\n\n\n\n\n\n
\n

Event:<\/b><\/p>\n<\/td>\n

\n

H.C. Wainwright 27th Annual Global Investment Conference<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Date:<\/b><\/p>\n<\/td>\n

\n

\nSeptember 8-10, 2025<\/p>\n<\/td>\n<\/tr>\n

\n

Virtual Presentation:<\/b><\/p>\n<\/td>\n

\n

\n7:00 AM, ET, September 8, 2025<\/p>\n<\/td>\n<\/tr>\n

\n

Registration:<\/b><\/p>\n<\/td>\n

\n

https:\/\/hcwevents.com\/annualconference\/<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nDuring the conference, Dr. Tucker will conduct one-on-one meetings with registered investors and potential partners, showcasing the company\u2019s business and clinical development strategy, recent corporate achievements, and anticipated milestones.<\/p>\n

About Enveric Biosciences<\/b><\/p>\n

\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric\u2019s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT\u2082A <\/sub>and 5-HT\u2081B <\/sub>receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.<\/p>\n

\nFor more information, please visit www.enveric.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric\u2019s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.<\/p>\n

\nA discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric\u2019s filings with the Securities and Exchange Commission, including Enveric\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250903174137\/en\/<\/a><\/span><\/p>\n

\nInvestor Relations
\n
Tiberend Strategic Advisors, Inc.
\n<\/a>
David Irish
\n
(231) 632-0002
\n
dirish@tiberend.com<\/a><\/p>\n

\nMedia Relations
\n
Tiberend Strategic Advisors, Inc.
\n<\/a>
Casey McDonald
\n
(646) 577-8520
\n
cmcdonald@tiberend.com<\/a><\/p>\n

KEYWORDS:<\/b> New York Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Mental Health Neurology Clinical Trials Other Health Biotechnology General Health Pharmaceutical Health Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City. In the prerecorded presentation, Dr. Tucker will provide updates and discuss progress for the Company’s pipeline of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003. Enveric designed EB-003 to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. … <\/p>\n

Continue reading “Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881529","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City. In the prerecorded presentation, Dr. Tucker will provide updates and discuss progress for the Company’s pipeline of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003. Enveric designed EB-003 to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. … Continue reading "Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T15:53:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference\",\"datePublished\":\"2025-09-03T15:53:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/\"},\"wordCount\":766,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/\",\"name\":\"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-09-03T15:53:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","og_description":"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City. In the prerecorded presentation, Dr. Tucker will provide updates and discuss progress for the Company’s pipeline of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003. Enveric designed EB-003 to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. … Continue reading \"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T15:53:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference","datePublished":"2025-09-03T15:53:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/"},"wordCount":766,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/","name":"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-09-03T15:53:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250903174137r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881529"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881529\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}